A single injection of a healthy gene allowed blind children to recognize objects, shapes, and even read — offering hope for ...

Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...

Revolutionary gene therapy approaches show promise in treating various retinal conditions, potentially transforming treatment ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...

PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...